Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Recombinant Novel Coronavirus vaccine

1 clinical trial

1 indication

Indication
COVID-19
Clinical trial
To Evaluate the Immunogenicity and Safety of Sequentially Enhanced Recombinant Novel Coronavirus Vaccine (CHO Cells) in Patients Aged 3-17 Years After Completion of Two Doses of Novel Coronavirus Inactivated Vaccine
Status: Completed, Estimated PCD: 2022-11-19